benefits of glp-1 receptor agonists In patients with #obesity, incretin-based therapies such as are reported to result in mean weight reductions approximately 15 to 20% along with additional health benefits, including decreased cardiovascular The cardiovascular effects of GLP-1

For short-term or mild adverse events, dietary modifications are warranted and, for constipation, increased fiber/water intake can be recommended

NG101 is an oral, small molecule peripherally acting dopamine D2 receptor antagonist that has recently completed a proof-of-concept safety and efficacy study in nausea and vomiting associated with glucagon-like peptide 1 (GLP-1) agonists and a Ph2 trial in gastroparesis

Edvardsson CE, Adermark L, Gottlieb S, Alfreji S, Emous TA, Gouda Y, Thorsell A, Vujii M, Arans C, Benrick A, Wernstedt Asterholm I, Lopez MF, Becker HC, Jerlhag E

Consequently, GLP-1 RAs were developed with molecular modifications that prolong their activity in vivo , enabling the development of once-weekly injectable preparations

The EMPA-REG OUTCOME trial showed that empagliflozin markedly reduced the risk of CV mortality compared to that observed with placebo [8]

& Foster-Schubert, K